{
    "clinical_study": {
        "@rank": "156410", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "description": "Group 1 will consist of 10 subjects with suspected MS, who have  had a clinical attack within the last 12 weeks,  have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication.  Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture."
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture."
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture."
            }
        ], 
        "biospec_descr": {
            "textblock": "Patients will provide blood and cerebrospinal fluid for use in this research."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis."
        }, 
        "brief_title": "Relaxin in Multiple Sclerosis (MS)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis, Relapsing-Remitting", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "The goal of this study is to obtain baseline information on serum and cerebrospinal fluid\n      (CSF)relaxin levels in patients with MS, as well as to further study RXFP-1 receptor binding\n      affinity for RLX in patients with active and clinically stable MS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with suspected MS, who have  had a clinical attack within the last 12 weeks,\n              have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken\n             within the prior 4 weeks, and for which they have not received any immunomodulating\n             or immunosuppressant medication.\n\n          -  Subjects with clinically stable definite MS, with no evidence of clinical relapse for\n             at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the\n             prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for\n             the Diagnosis of MS.\n\n          -  Subjects without evidence of inflammatory systemic or inflammatory central nervous\n             system disease, who require CSF removal for some other cause, such treatment of\n             benign intracranial hypertension or as part of the procedure for insertion of an\n             intrathecal medication delivery system.\n\n        Exclusion Criteria:\n\n        - Pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with suspected MS undergoing a lumbar puncture for diagnosis, patients with\n        stable MS willing to participate in the study, and patients without MS having a lumbar\n        puncture as part of their non-MS disease management will be invited to participate in this\n        study."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909492", 
            "org_study_id": "13-089B"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "Patients will provide a serum sample for research.", 
                "intervention_name": "Blood Draw", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "Patients will have a lumbar puncture to obtain CSF.", 
                "intervention_name": "Lumbar Puncture", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Spinal tap", 
                    "LP"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis", 
            "MS", 
            "Relaxin"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "Crystal.Turner2@providence.org", 
                "last_name": "Crystal Turner", 
                "phone": "503-216-1017"
            }, 
            "contact_backup": {
                "email": "Chiayi.Chen@providence.org", 
                "last_name": "Chiayi Chen, RN, PhD", 
                "phone": "(503) 216-1012"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97225"
                }, 
                "name": "Providence MS Center"
            }, 
            "investigator": [
                {
                    "last_name": "Stanley Cohan, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Kiren Kresa-Reahl, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hubert Leonard, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Harry Reahl, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kyle Smoot, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis", 
        "overall_official": {
            "affiliation": "Providence Brain & Spine Institute, Providence Health & Services", 
            "last_name": "Stanley Cohan, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "There is no information available on what serum and CSF levels of RLX are observed in patients with active versus stable relapsing MS, how these values compare to that found in human volunteers without MS or other inflammatory diseases, and whether RLX functions normally in subjects with active or stable MS.", 
            "measure": "Relaxin (RLX) Levels", 
            "safety_issue": "No", 
            "time_frame": "During diagnostic LP"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909492"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Providence Health & Services", 
        "sponsors": {
            "collaborator": {
                "agency": "Providence Brain & Spine Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Providence Health & Services", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}